Given the rarity of NTRK fusions, the company is also rolling out a free testing program to identify NTRK fusion-positive patients who would benefit from treatment.
With studies showing BRCA-mutated patients have a greater magnitude of benefit, oncologists grapple with complex treatment decisions in BRCA mutation-free cases.
The gap in care suggests that more education and decision support tools are needed to help physicians prescribe drugs based on highly actionable tumor alterations, researchers said.
Results show population screening can pick up risky BRCA1/2 mutations in men and women from Ashkenazi Jewish populations in the US, though engagement challenges remain.
At ASCO, Blueprint presented positive data on its RET inhibitor pralsetinib across a range of cancers and in a call with investors discussed regulatory plans in lung and thyroid cancers.
